

Reference Data

Fiscal Year 2018
(April 1, 2018 to March 31, 2019)

Consolidated Earnings

• Consolidated Financial Data	P .1
• Consolidated Balance Sheets	P .2
• Consolidated P/L Statement	P .3
• Consolidated Sales Breakdown by Segment/Category	P .4
• Consolidated Operating Profit by Segment	P .4
• Consolidated Sales - Leading Brands of Self-Medication Operations	P .5
• Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations	P .6
• Capital Expenditure	P .7
• Depreciation and Amortization	P .7
• R&D Expenses	P .7
• Results of Major Consolidated Subsidiaries	
♦ Taisho Pharmaceutical	P .8
♦ Taisho Toyama Pharmaceutical (currently Taisho Pharma)	P .8
♦ Biofermin Pharmaceutical	P .8
• Major Subsidiaries and Affiliates	P .9
• Shareholders Information	P.10
• Prescription Pharmaceutical Operations: New Drug Development-Taisho Pharmaceutical	P.11
• Status of New Products	P.13

Consolidated Financial Data

(Millions of yen)

	March 2016 (FY2015)	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	(Est)	
					March 2020	
					2Q(4-9)	Full year
Net sales	290,135	279,773	280,092	261,551	126,500	253,500
(YOY%)	(-0.1%)	(-3.6%)	(+0.1%)	(-6.6%)	(-2.3%)	(-3.1%)
Self-Medication operations	180,722	179,992	183,996	180,123	92,000	185,500
Prescription Pharmaceutical operations	109,413	99,781	96,096	81,428	34,500	68,000
Gross profit on sales*	176,813	178,226	182,984	170,163	86,100	172,000
Selling, general and administrative expenses	147,935	146,260	146,007	138,951	69,600	136,500
Research and development expenses (% Sales)	21,768 (7.5%)	21,260 (7.6%)	21,150 (7.6%)	20,801 (8.0%)	11,500 (9.1%)	22,600 (8.9%)
Advertising expenses	21,366	22,087	22,579	20,206	11,700	23,100
Sales promotion expenses	31,775	30,079	28,636	27,125	14,500	27,900
Personnel expenses	36,042	35,845	35,241	32,491	13,900	27,500
Operating Profit	28,878	31,966	36,977	31,211	16,500	35,500
(YOY%)	(-9.7%)	(+10.7%)	(+15.7%)	(-15.6%)	(-2.9%)	(+13.7%)
Ordinary Profit	36,775	38,036	42,140	40,851	20,000	42,500
(YOY%)	(-7.1%)	(+3.4%)	(+10.8%)	(-3.1%)	(-11.9%)	(+4.0%)
Profit attributable to owners of parent	22,473	28,781	31,679	48,593	13,500	28,500
(YOY%)	(-8.4%)	(+28.1%)	(+10.1%)	(+53.4%)	(-68.2%)	(-41.4%)
Comprehensive income	9,059	30,184	36,627	48,027	-	-
(YOY%)	(-81.1%)	(+233.2%)	(+21.3%)	(+31.1%)	-	-
Basic EPS (yen)	277.75	360.18	396.54	608.80	169.15	357.11
Diluted EPS (yen)	277.59	359.92	396.20	608.22	168.98	356.73
BPS (yen)	7,870.04	8,127.87	8,452.12	8,924.23	9,027.24	9,161.15
Dividend per share (yen)	100.00	110.00	110.00	120.00	50.00	110.00
Payout ratio	36.0%	30.5%	27.7%	19.7%	-	30.8%
Capital expenditure	8,967	7,011	4,857	5,259	2,360	5,530
Depreciation and amortization	11,117	10,423	10,154	10,073	4,410	9,260
Total assets**	758,904	770,685	799,616	821,782	829,000	841,000
Shareholders' equity	643,127	665,088	691,318	724,137	732,000	743,000
Return on equity (%)***	3.5%	4.5%	4.8%	7.0%	-	3.9%
Return on assets (%)***	2.9%	3.8%	4.0%	6.0%	-	3.4%
Equity ratio (%)**	82.9%	84.3%	84.4%	86.7%	86.9%	86.9%
Overseas sales	29,901	27,529	30,936	30,978	16,300	32,500
Overseas sales ratio (% of total sales)	10.3%	9.8%	11.0%	11.8%	12.9%	12.8%
Number of employees	6,517	6,461	6,340	5,142	-	-

* After provision/reversal of reserve for returned unsold goods

** In accordance with the partial modification of the deferred tax accounting standard, a retroactive adjustment was conducted for total assets/equity ratio relating to the fiscal years ended March 2016 to March 2018

*** Average of the beginning and year-end balance of shareholders' equity / total assets

Consolidated Balance Sheets

(Millions of yen)

	End of FY2017*		End of FY2018		change	
	(March 31, 18)	% total	(March 31, 19)	% total		
(Assets)						
I Current assets:	356,161	44.5%	469,781	57.2%	+113,620	
Cash and deposits	219,973		282,567		+62,593	
Notes and accounts receivable-trade	75,268		71,286		-3,982	
Marketable securities	29,739		75,900		+46,160	Transfer from investment securities +74,500, Redemption of bonds ▲26,000
Inventories	26,844		29,517		+2,673	
Other	4,335		10,509		+6,174	
II Fixed assets:	443,455	55.5%	352,001	42.8%	-91,454	
(1) Tangible fixed assets:	93,716	(11.7%)	91,283	(11.1%)	-2,432	
Buildings and structures	47,536		45,764		-1,772	
Machinery, equipment and vehicles	5,449		5,217		-231	
Land	37,021		37,008		-12	
Other	3,708		3,292		-416	
(2) Intangible fixed assets:	31,116	(3.9%)	24,302	(3.0%)	-6,814	
Goodwill	15,347		12,534		-2,813	
Sales rights	2,740		1,419		-1,321	
Trademarks	8,750		5,657		-3,093	
Software	3,627		4,086		+459	
Other	650		604		-45	
(3) Investments and other assets:	318,622	(39.8%)	236,416	(28.8%)	-82,206	
Investment securities	236,797		172,432		-64,365	Transferred to investments in securities▲74,500, Purchase of bonds+18,867, Valuation difference ▲8,580
Shares of subsidiaries and affiliates	65,294		31,262		-34,031	Sales of shares of Toyama Chemical Co., Ltd. and others
Net defined benefit assets	3,230		5,765		+2,534	
Deferred tax assets	11,806		9,365		-2,441	
Other	1,492		17,590		+16,097	
Total assets	799,616	100.0%	821,782	100.0%	+22,166	
(Liabilities)						
I Current liabilities:	60,299	7.5%	58,453	7.1%	-1,846	
Notes and accounts payable-trade	19,939		18,814		-1,124	
Accounts payable	14,275		14,276		+1	
Accrued income taxes	8,614		8,607		-6	
Provision for bonuses	3,874		3,123		-750	
Other	13,595		13,630		+34	
II Long-term liabilities:	47,998	6.0%	39,192	4.8%	-8,806	
Net defined benefit liabilities	23,391		18,715		-4,676	
Deferred taxes liabilities	16,970		13,530		-3,440	
Other	7,637		6,946		-690	
Total liabilities	108,298	13.5%	97,645	11.9%	-10,652	
(Net assets)						
I Shareholders' equity	643,655	80.5%	683,025	83.1%	+39,369	
Common stock	30,000	3.8%	30,000	3.7%	-	
Capital surplus	15,271	1.9%	14,924	1.8%	-347	
Retained earnings	666,920	83.4%	706,742	86.0%	+39,821	Profit attributable to owners of parent+48,593, Dividend on retained earnings▲8,788
Treasury stock	-68,536	-8.6%	-68,641	-8.4%	-104	
II Accumulated other comprehensive income	31,009	3.9%	29,258	3.6%	-1,750	
Valuation difference on securities	37,970	4.7%	32,017	3.9%	-5,952	
Deferred gains or losses on hedges	-0	-0.0%	2,181	0.3%	+2,181	
Foreign currency translation adjustment	-1,704	-0.2%	-2,130	-0.3%	-425	
Remeasurements of defined benefit plans	-5,256	-0.7%	-2,809	-0.3%	+2,447	
III Share acquisition rights	565	0.1%	687	0.1%	+121	
IV Non-controlling interests	16,087	2.0%	11,165	1.4%	-4,921	
Total net assets	691,318	86.5%	724,137	88.1%	+32,819	
Total liabilities and net assets	799,616	100.0%	821,782	100.0%	+22,166	

* The figures for the preceding fiscal year have been revised retrospectively following the partial revision to the Accounting Standards for Tax Effect Accounting.

Consolidated P/L Statement

(Millions of yen)

	End of FY2017		End of FY2018		YOY change	
	(March 31, 18)	% total	(March 31, 19)	% total		
Net sales	280,092	100.0%	261,551	100.0%	-18,541	
Cost of sales	97,154	34.7%	91,206	34.9%	-5,948	
Gross profit on sales	182,938	65.3%	170,345	65.1%	-12,593	
Provision for sales returns	-46		182		+228	
Gross profit	182,984	65.3%	170,163	65.1%	-12,821	
Selling, general and administrative expenses	146,007	52.1%	138,951	53.1%	-7,055	
Research and development expenses	21,150		20,801		-349	
Advertising expenses	22,579		20,206		-2,372	
Sales promotion expenses	28,636		27,125		-1,511	
Personnel expenses	35,241		32,491		-2,749	
Other	38,399		38,326		-72	
Operating Profit	36,977	13.2%	31,211	11.9%	-5,765	
Non-operating income	7,479	2.7%	9,774	3.7%	+2,295	Equity in gains of affiliates 1,689
Non-operating expenses	2,316	0.8%	135	0.1%	-2,181	FY2017: Equity in losses of affiliates 1,634
Ordinary Profit	42,140	15.0%	40,851	15.6%	-1,289	
Extraordinary income	6,218	2.2%	42,982	16.4%	+36,763	Gain on sales of shares of subsidiaries and associates 42,944
Extraordinary losses	288	0.1%	19,349	7.4%	+19,061	Early retirement program-expenses 12,866 , Impairment loss 2,916
Profit before income taxes and minority interests	48,070	17.2%	64,484	24.7%	+16,413	
Income taxes	14,701	5.2%	14,658	5.6%	-42	
Profit	33,368	11.9%	49,825	19.0%	+16,456	
Profit attributable to non-controlling interests	1,689	0.6%	1,231	0.5%	-458	
Profit attributable to owners of parent	31,679	11.3%	48,593	18.6%	+16,914	

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2016 (FY2015)	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	(Est) March 2020	
					2Q(4-9)	Full year
					Self-Medication operations (YOY%)	180,722 (+2.5%)
Japan	148,125	149,733	150,191	145,983	74,500	150,500
Overseas	29,875	27,507	30,921	30,867	16,200	32,300
Other	2,721	2,751	2,884	3,272	1,300	2,700
Prescription Pharmaceutical operations (YOY%)	109,413 (-4.2%)	99,781 (-8.8%)	96,096 (-3.7%)	81,428 (-15.3%)	34,500 (-13.1%)	68,000 (-16.5%)
Ethical drugs	107,215	96,126	91,259	79,460	33,300	66,500
Other	2,197	3,655	4,837	1,967	1,200	1,500
Total	290,135	279,773	280,092	261,551	126,500	253,500

Consolidated Operating Profit by Segment

(Millions of yen)

	March 2016 (FY2015)	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	(Est) Mar-20	
					2Q(4-9)	Full year
					Self-Medication operations (YOY%)	28,393 (-8.6%)
Prescription Pharmaceutical operations (YOY%)	1,755 (-15.5%)	3,352 (+90.9%)	8,207 (+144.8%)	2,685 (-67.3%)	1,900 (+54.7%)	3,500 (+30.3%)
Other* (YOY%)	-1,271 (-)	-1,492 (-)	-1,393 (-)	-1,760 (-)	-700 (-)	-1,500 (-)
Total	28,878	31,966	36,977	31,211	16,500	35,500

* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of Yen)

	March 2016 (FY2015)	March 2017 (FY2016)	March 2018 (FY2017)	March 2019		(Est) March 2020		
				(FY2018)	YOY	2Q(4-9)	Full year	YOY
Japan	148.1	149.7	150.2	146.0	-2.8%	74.5	150.5	+3.1%
<i>Lipovitan</i> series	60.5	58.5	54.7	52.0	-4.9%	29.2	52.7	+1.3%
<i>Pabron</i> series	24.8	26.3	28.9	28.9	+0.2%	11.7	29.1	+0.7%
<i>RiUP</i> series	16.5	16.1	16.5	15.3	-7.3%	7.7	15.3	-0.0%
<i>Biofermin</i> series	7.5	8.8	8.6	10.2	+17.9%	5.3	10.6	+3.9%
<i>VICKS</i> series	3.6	3.6	4.0	4.0	-0.5%	1.6	4.1	+2.9%
GI treatment series	4.1	4.0	3.9	3.7	-5.6%	1.6	3.6	-3.3%
<i>Livita</i> series	3.9	3.8	3.5	3.4	-1.9%	1.7	3.6	+5.0%
<i>NARON</i> series	3.7	3.4	3.2	3.0	-4.2%	1.5	3.0	-0.5%
<i>Colac</i> series	3.3	3.3	3.3	3.0	-7.4%	1.5	3.1	+4.1%
Overseas	29.9	27.5	30.9	30.9	-0.2%	16.2	32.3	+4.6%
Energy drinks	10.3	9.4	10.8	11.5	+6.0%	5.9	11.7	+1.8%
OTC drugs	18.4	17.2	18.6	18.0	-3.0%	9.8	19.4	+7.6%
Others	2.7	2.8	2.9	3.3	+13.5%	1.3	2.7	-17.5%

(Rounded to the nearest hundred-million)

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2016 (FY2015)	March 2017 (FY2016)	March 2018 (FY2017)	March 2019		(Est) March 2020		
				(FY2018)	YOY	2Q(4-9)	Full year	YOY
Lipovitan series	60.5	58.5	54.7	52.0	-4.9%	29.2	52.7	+1.3%
<i>Lipovitan D</i>	38.6	37.2	35.3	33.4	-5.4%	18.4	32.7	-2.0%
Others	21.9	21.3	19.5	18.7	-3.9%	10.8	20.1	+7.4%
(100mL other <i>Lipovitan</i>)	13.9	13.5	12.7	12.3	-2.7%	7.0	13.1	+6.4%
(50mL other <i>Lipovitan</i>)	8.0	7.7	6.8	6.4	-6.3%	3.8	7.0	+9.4%

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations

(Billions of Yen)

	March 2016 (FY2015)	March 2017 (FY2016)	March 2018 (FY2017)	March 2019		(Est) March 2020		
				(FY2018)	YOY	2Q(4-9)	Full year	YOY
<i>Edirol</i>	19.8	22.6	25.4	26.2	+3.2%	14.0	27.7	+5.7%
<i>Bonviva</i>	4.9	5.9	6.5	6.4	-1.8%	3.3	6.8	+6.5%
<i>Lusefi</i>	0.9	2.9	5.0	5.6	+13.0%	3.3	6.7	+19.3%
<i>Clarith</i>	12.0	9.3	7.7	5.3	-30.4%	1.9	4.0	-24.9%
<i>LOQOA</i>	0.4	1.8	3.1	3.5	+14.0%	1.9	3.9	+12.1%
<i>Biofermin</i>	3.6	3.9	4.0	3.9	-1.1%	1.9	3.9	-1.1%
<i>Geninax</i>	4.3	5.2	4.4	3.5	-20.5%	1.5	3.3	-5.9%
<i>Palux</i>	6.2	5.4	4.9	3.5	-27.1%	1.6	3.1	-12.6%
<i>ZOSYN</i>	27.3	15.5	9.8	6.1	-38.1%	-	-	-
<i>OZEX</i>	5.9	4.9	3.6	2.8	-22.1%	-	-	-

(Rounded to the nearest hundred-million)

Consolidated: Capital Expenditure

(Millions of yen)

	March 2016 (FY2015)	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	(Est) March 2020	
					2Q(4-9)	Full year
					Total capital expenditure	8,967
Taisho Pharmaceutical	7,324	6,013	4,054	3,974	1,960	4,520
Production department	919	1,104	1,331	1,061	750	1,870
Research department	1,053	893	1,084	979	170	530
Head Office and the others	5,351	4,015	1,638	1,932	1,040	2,120
Other subsidiaries	1,642	998	803	1,285	400	1,010

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2016 (FY2015)	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	(Est) March 2020	
					2Q(4-9)	Full year
					Depreciation and amortization	11,117
Cost of sales	3,823	3,411	3,085	3,225	1,610	3,570
SGA expenses	7,293	7,011	7,068	6,847	2,800	5,690

Consolidated: R&D Expenses

(Millions of yen)

	March 2016 (FY2015)	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	(Est) March 2020	
					2Q(4-9)	Full year
					Total R&D expenses	21,768
Self-Medication operations	5,497	5,497	5,983	5,353	3,400	6,400
Prescription Pharmaceutical operations	16,270	15,763	15,167	15,447	8,100	16,200

Results of Major Consolidated Subsidiaries

Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 2016 (FY2015)	March 2017 (FY2016)	March 2018 (FY2017)	March 2019		(Est) March 2020		
				(FY2018)	YOY	2Q(4-9)	Full year	YOY
Net Sales	198.4	203.1	205.2	192.9	-6.0%	109.0	219.0	+13.5%
Self-Medication	150.1	152.0	151.9	147.7	-2.8%	75.0	151.0	+2.2%
Prescription Pharmaceutical	48.3	51.1	53.2	45.2	-15.2%	34.0	68.0	+50.6%
Operating profit	19.5	23.1	25.9	20.3	-21.6%	13.0	29.0	+42.7%
Ordinary profit	24.3	26.5	33.6	27.9	-17.2%	17.0	36.0	+29.2%
Profit	17.8	20.1	28.2	11.5	-59.1%	13.0	28.0	+142.9%

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical

(Billions of Yen)

	March 2016 (FY2015)	March 2017 (FY2016)	March 2018 (FY2017)	March 2019	
				(FY2018)	YOY
Net Sales	107.2	96.1	91.3	79.5	-12.9%
Operating profit	2.7	2.0	2.7	3.0	+10.0%
Ordinary profit	2.7	2.1	2.7	3.1	+13.9%
Profit	1.4	1.3	1.7	0.3	-82.2%

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical are included in the consolidated results of Prescription Pharmaceutical operations.

Sales and earnings of Biofermin Pharmaceutical

(Billions of Yen)

	March 2016 (FY2015)	March 2017 (FY2016)	March 2018 (FY2017)	March 2019	
				(FY2018)	YOY
Net Sales	9.7	10.6	10.9	11.5	+6.1%
Self-Medication	6.6	7.3	7.4	8.0	+9.0%
Prescription Pharmaceutical	3.1	3.4	3.5	3.5	+0.1%
Operating profit	2.3	2.7	3.2	3.2	-0.2%
Ordinary profit	2.3	2.7	3.1	3.3	+5.7%
Profit	1.6	1.9	2.2	2.3	+4.3%

(Rounded to the nearest hundred-million)

Major Subsidiaries and Affiliates

(As of March 31, 2019)

Company	Address	Capital	Business	Ownership*
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 29,837,892	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co.,Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co.,Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co.,Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	63.9
Taisho Toyama Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 100,000	PD	100.0
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Dr. Program Co., Ltd.	Tokyo, Japan	,000 Yen 251,500	SMG	100.0
Taisho Pharmaceutical (Taiwan) Co.,Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co.,Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co.,Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 165,300	SMG	100.0
Osotspa Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.6
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,000	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
(2) Equity accounting method				
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.1
Duoc Hau Giang Pharmaceutical JSC	Vietnam	,000 VND 1,307,460,710	SMG	35.0

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

*Ownership: including the portion of indirect ownership

Shareholders Information (as of end of March 2019)

Major Shareholders

(Thousands of Shares)

Shareholders	Number of shares	% of total
The Uehara Memorial Foundation	15,000	18.78%
Shoji Uehara	7,874	9.86%
Uehara Museum	3,900	4.88%
Sumitomo Mitsui Banking Corp.	3,000	3.76%
MUFG Bank, Ltd.	3,000	3.76%
The Master Trust Bank of Japan, Ltd. (Trust account)	2,170	2.72%
Akira Uehara	2,143	2.68%
Japan Trustee Services Bank, Ltd. (Trust account)	1,670	2.09%
Kajima Corporation	1,650	2.07%
Japan Trustee Services Bank, Ltd. (Sumitomo Mitsui Trust Bank, Limited ReTrust Account/ Sumitomo Chemical Company, Limited Employee Pension Trust Account)	1,530	1.92%

Shares less than one thousand are rounded down.

Treasury stock of 10,255 thousand shares are excluded from the above as these shares do not have voting rights.

The shareholding ratio is calculated excluding treasury stock. (Rounded to the nearest second decimal place)

Distribution of Ownership Among Shareholders

	% of total
Financial Institutions	20.95%
Financial Instruments Firms	0.53%
Other companies	39.20%
Foreign Companies	14.24%
Individuals and Others	25.08%
Total	100.00%

The shareholder composition is calculated excluding treasury stock of 10,255 thousand shares.

(Rounded to the nearest second decimal place)

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of May 13, 2019

In Japan

Phase 3

TS-152 (Injection)

- < Application > Rheumatoid arthritis
- < Development > In-license (Licensor: Ablynx)
- < Description > Anti-TNF(Tumor Necrosis Factor)- α antibody
- < Remarks > Generic name: Ozoralizumab

Phase 2

TS-091 (Oral)

- < Application > Central disorders of hypersomnolence
- < Development > In-house

TS-141 (Oral)

- < Application > Childhood Attention-Deficit/Hyperactivity Disorder
- < Development > In-house

TS-133 (Topical)

- < Application > Alopecia
- < Development > In-house

TS-142 (Oral)

- < Application > Insomnia
- < Development > In-house

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of May 13, 2019

Overseas

Phase 2

TS-121 (Oral)

< Application > Depression

< Development > In-house

Phase 1

TS-091 (Oral)

< Target disease > Central disorders of hypersomnolence

< In-house/Licensed-in > In-house

TS-134 (Oral)

< Target disease > Schizophrenia

< In-house/Licensed-in > In-house

TS-161 (Oral)

< Target disease > Depression

< In-house/Licensed-in > In-house

Launch of New Products

As of May 13, 2019

New Products Since FY2018 3Q Earnings Announcement (Jan 30, 2019)

Self-Medication Operations

Coppertone Kireimise UV marshmallow skin

Coppertone Kireimise UV KiraKira skin

< Description > A sunscreen developed to avoid damage from the sun, while making the skin look beautiful. Two types are available depending on the desired skin of the user.

< Launch > Feb 2019

Pabron Sa

< Description > A combination cold remedy that can be used in households with small children. The ingredients are effective for a variety of cold symptoms including cough, sore throat, stuffy nose and fever.

< Launch > Feb 2019

RAIZIN SAKURA

< Description > An exclusive spring flavor with a cherry blossom-like scent, sweet and fresh aftertaste as well as a cherry-blossom color. It is ideal for business people who want a fresh start on fulfilling work and hobbies.

< Launch > Feb 2019

Semper Ramucure

< Description > Available for children aged 5 years and older. Chewable carsickness pill with firmness similar to ramune. The grape flavor which is popular among children was used. It can be taken without water when away from home.

< Launch > Mar 2019

COBARASAPŌTO R

< Description > A collaboration product with *RIZAP*. A diet support drink that provides a feeling of fullness when you are hungry, thanks to Taisho Pharmaceutical's original Cobara sensor technology.

< Launch > Mar 2019

Lipovitan D Kingdom "Shutsujin! Craft Pack" *mail order

< Description > A limited collaboration product between *Lipovitan D* and the anime series "Kingdom," featuring 15 popular characters on the bottles. It comes with a paper version of the bugu (weapon) that appears in the show.

< Launch > Mar 2019

Launch of New Products

As of May 13, 2019

New Products Since FY2018 3Q Earnings Announcement (Jan 30, 2019)

Self-Medication Operations

Taisho Kaki (oyster) Extract *mail order

- < Description > A supplement produced using the special pressure enzymatic decomposition method, with pressure enzymatic decomposition Kaki (oyster) extract as its main ingredient. It contains many nutrients such as oyster peptides, zinc, glycogen, amino acids and calcium.
- < Launch > Mar 2019
-

Colac Mg

- < Description > A constipation drug that contains magnesium oxide, a non-irritant ingredient. Magnesium oxide collects water in the intestines and softens hardened stools to show its effect.
- < Launch > Apr 2019
-

Fiber plus care

- < Description > It contains an original balance of six types of plant-derived dietary fiber and lactic acid bacteria from Biofermin Pharmaceutical. Green juice is ideal for those looking for a simple way to improve their diet.
- < Launch > Apr 2019
-

Taisho Stomatitis Chewable Tablet

- < Description > A stomatitis drug that is easy for children (aged 7 years and older) to take who have difficulty swallowing a tablet, because it is a chewable tablet taken without water. It is also recommended for stomatitis that occurs at a place inside the mouth that is difficult to reach with external medicine.
- < Launch > Apr 2019
-

Lipovitan D : Japanese professional baseball teams bottle(Hiroshima Toyo Carp)

- < Description > Limited edition bottles featuring the Hiroshima Carp are launched as this season's first Lipovitan D Professional Baseball Team Bottle, which was popular in the previous season. There are four bottle designs available.
- < Launch > Apr 2019
-

Lipovitan Rhythm

- < Description > In addition to taurine and a variety of vitamins, it contains royal jelly, which contains a variety of nutrients. With a refreshing citrus flavor, it is recommended for those who want to have an enjoyable time on and off duty, and to maintain their physical fitness to get through the day.
- < Launch > Apr 2019 (Available nationwide)
-

Launch of New Products

As of May 13, 2019

New Products Since FY2018 3Q Earnings Announcement (Jan 30, 2019)

Self-Medication Operations

Lipovitan Alcoveil

< Description > A refreshing, pineapple-flavored beverage that contains 1 billion live lactic acid bacteria per bottle (derived from rice), in addition to curcumin and turmeric extract.

< Launch > Apr 2019 (Available nationwide)

Lipovitan D : Reiwa bottle *mail order

< Description > Welcoming the third era since the launch of Lipovitan D, Reiwa is printed on the front of the bottle in commemoration.

< Launch > Apr 2019

RAIZIN MOJITO

< Description > A seasonal summer flavor. In addition to the clean, refreshing and sweet mojito flavor, it has a light green color reminiscent of mint. It is ideal for business people who want to be fulfilled at work and during hobbies while feeling refreshed this summer.

< Launch > Apr 2019
